Cytochrome P450 3A4 induction: Lumacaftor versus ivacaftor?

(Bentham Science Publishers) Cystic fibrosis is a disease caused by genetically defective CFTR proteins. The recent approval of lumacaftor combined with ivacaftor targets 70 percent of CF patients with F508del-CFTR. Unfortunately, our understanding of the way these drugs move (pharmacokinetics) and work (pharmacodynamics) in the human body is limited. For the first time, researchers have investigated potential cytochrome interactions of ivacaftor, its major metabolites, lumacaftor and tezacaftor which could result in reduced concentrations of the drug, causing reduced efficacy.
Source: EurekAlert! - Biology - Category: Biology Source Type: news